Suppr超能文献

致死性中线肉芽肿-鼻型自然杀伤/T细胞淋巴瘤

Lethal midline granuloma-nasal natural killer/T-cell lymphoma.

作者信息

Mendenhall William M, Olivier Kenneth R, Lynch James W, Mendenhall Nancy Price

机构信息

Department of Radiation Oncology, University of Florida College of Medicine, Gainesville, FL, USA.

出版信息

Am J Clin Oncol. 2006 Apr;29(2):202-6. doi: 10.1097/01.coc.0000198738.61238.eb.

Abstract

PURPOSE

The purpose of this paper is to discuss lethal midline granuloma (LMG)-nasal natural killer (NK) T-cell lymphoma (LMG-NTL).

METHODS

Literature review.

RESULTS

LMG is a rare entity that usually arises in the nasal cavity, exhibits a male preponderance, and has a wide age range. The majority of LMGs are LMG-NTLs. The optimal treatment of LMG-NTL is unclear and is most likely moderate-dose radiotherapy. The prognosis for patients with LMG-NTL is significantly worse than for patients with other types of head and neck non-Hodgkin lymphomas (NHL). The 5-year survival rate is approximately 20% but may be higher, depending on whether patients with less aggressive forms of NHL are included. Initial local-regional disease progression is the predominant pattern of treatment failure. Late failures after 5 years are uncommon.

CONCLUSIONS

LMG-NTL is a rare nasal NK/T-cell lymphoma that can be difficult to distinguish from other benign and malignant entities. Its clinical course, however, is extremely aggressive. The patterns of failure suggest a role for more aggressive local-regional treatment, as well as more effective chemotherapy.

摘要

目的

本文旨在探讨致死性中线肉芽肿(LMG)-鼻型自然杀伤(NK)T细胞淋巴瘤(LMG-NTL)。

方法

文献综述。

结果

LMG是一种罕见的疾病,通常发生于鼻腔,男性多见,发病年龄范围广。大多数LMG为LMG-NTL。LMG-NTL的最佳治疗方法尚不清楚,最可能是中等剂量放疗。LMG-NTL患者的预后明显差于其他类型的头颈部非霍奇金淋巴瘤(NHL)。5年生存率约为20%,但可能更高,这取决于是否纳入了侵袭性较低的NHL患者。初始局部区域疾病进展是治疗失败的主要模式。5年后的晚期失败并不常见。

结论

LMG-NTL是一种罕见的鼻型NK/T细胞淋巴瘤,可能难以与其他良性和恶性疾病相鉴别。然而,其临床病程极具侵袭性。失败模式提示更积极的局部区域治疗以及更有效的化疗可能发挥作用。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验